Why are non‑steroidal anti‑inflammatory drugs (NSAIDs) contraindicated in patients with a cardiac history such as coronary artery disease, prior myocardial infarction, heart failure, uncontrolled hypertension, or cerebrovascular disease?

NSAIDs Increase Risk of Heart Attack, Stroke, Heart Failure, and Hypertension in Cardiac Patients

NSAIDs should be avoided in patients with cardiac history because they significantly increase the risk of myocardial infarction, stroke, heart failure exacerbation, and hypertension—with the cardiovascular risk being greatest in those with prior cardiovascular disease or at high risk. 1

Primary Cardiovascular Mechanisms

NSAIDs cause cardiovascular harm through multiple pathways:

• Increased thrombotic events: Both COX-2 selective and non-selective NSAIDs elevate myocardial infarction and stroke risk
• Heart failure exacerbation: NSAIDs promote fluid retention and worsen cardiac function 2
• Blood pressure elevation: Hypertension worsening occurs through renal sodium retention
• Interference with aspirin cardioprotection: Ibuprofen specifically blocks aspirin's antiplatelet effect 1

Risk Magnitude in Cardiac Patients

The evidence demonstrates substantial harm:

• Danish registry data showed NSAID use increased death or MI risk up to 5-fold in patients with prior MI or heart failure 3
• Risk appears immediately at treatment initiation—no safe treatment window exists 3
• Among cardiac patients in Denmark, 35-44% were still exposed to NSAIDs despite guidelines discouraging use 3
• In patients with prior MI, ibuprofen increased acute coronary syndrome risk (OR 1.63) especially in the second year post-event 4

Specific NSAID Risks (Ranked by Cardiovascular Danger)

Highest risk:

• Ketorolac: Oral use shows OR 3.91 for new MI 4
• Rofecoxib (withdrawn): Fatal cardiovascular events even at low doses after 7 days (HR 2.5), with OR 2.30 for new MI 4
• Diclofenac: High cardiovascular risk comparable to COX-2 inhibitors 4

Moderate-high risk:

• Celecoxib: Risk increases from day 14 (HR 2.3), OR 1.47 for new MI 4
• Ibuprofen: Increases stroke risk (HR 1.23) and acute coronary syndrome 4

Lower cardiovascular risk (but not risk-free):

• Naproxen: Lower cardiovascular death risk but significantly higher gastrointestinal bleeding, which increases fatal events and comorbidity in cardiac patients (HR 1.44 in first year) 4

Critical Clinical Pitfalls

Aspirin interaction: Ibuprofen blocks aspirin's irreversible platelet inhibition. If both must be used:

• Take ibuprofen ≥30 minutes after immediate-release aspirin, OR
• Take ibuprofen ≥8 hours before aspirin 1
• No safe timing recommendations exist for enteric-coated aspirin with ibuprofen 1

Dose-response relationship: Higher NSAID doses correlate with increased cardiovascular events, supporting causality 3

First 90 days most dangerous: Initial NSAID exposure period carries highest risk 5

When NSAIDs Cannot Be Completely Avoided

The American Heart Association guideline states clearly: In patients with prior cardiovascular disease or high cardiovascular risk, NSAIDs should be limited to patients for whom there are no appropriate alternatives, and then only in the lowest dose and for the shortest duration necessary 1

Protective factors that may mitigate (but not eliminate) risk:

• Concurrent antiplatelet therapy: OR reduced from 1.79 to 1.37 with antiplatelet use 4
• Statin therapy shows cardioprotective effects in NSAID users 4

Alternative Approach

Consider acetaminophen (paracetamol) as it does not interfere with aspirin's antiplatelet effect 1 and lacks the same cardiovascular risk profile, though it has hepatotoxicity concerns at high doses.

The evidence is unequivocal: NSAIDs pose substantial cardiovascular danger in patients with cardiac history, with risk present from treatment initiation and increasing with dose and duration. The widespread use despite guidelines (35-44% of cardiac patients exposed) represents a major public health concern 3.